TScan Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. TScan Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 56% to $21,049,000. Profit margin reached -424%. Total operating expenses were $114,507,000.
Profit Margin
| 2019 | 0 | -13.10M | |
|---|---|---|---|
| 2020 | 1.08M | -26.02M | -2398.25% |
| 2021 | 10.14M | -48.62M | -479.49% |
| 2022 | 13.53M | -65.80M | -486.19% |
| 2023 | 21.04M | -89.21M | -423.86% |
TCRX Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 21.04M | 13.53M | 10.14M | 1.08M | 0 |
Cost of revenue | 88.15M | 5.13M | 3.32M | 20.57M | 519K |
Gross profit | -67.10M | 8.39M | 6.81M | -19.49M | -519K |
Operating exp. | |||||
Research and development | 88.15M | 59.81M | 44.95M | 20.57M | 9.44M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 114.50M | 80.17M | 58.78M | 27.31M | 14.21M |
Operating income | -93.45M | -66.63M | -48.64M | -26.23M | -14.21M |
Other income (expenses), net | 4.24M | 415K | 16K | 106K | 552K |
Income before tax | -89.21M | -66.22M | -48.62M | -26.12M | -13.65M |
Income tax expense | 0 | -415K | 0 | -106K | -552K |
Net income | -89.21M | -65.80M | -48.62M | -26.02M | -13.10M |
Earnings per share | |||||
Basic EPS | -1.36 | -2.74 | -2.03 | -1.04 | -0.53 |
Diluted EPS | -1.36 | -2.74 | -2.03 | -1.04 | -0.53 |
| Data source | Data source | Data source |